Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Syngene International Ltd. ( (IN:SYNGENE) ) has shared an update.
Syngene International Ltd. announced the approval of its audited financial results for the quarter and year ending March 31, 2025, and recommended a final dividend of Re.1.25 per equity share. The board also approved the appointment of V Sreedharan & Associates as secretarial auditors and decided on several corporate governance matters, including managerial remuneration and amendments to incentive plans, all subject to shareholder approval.
More about Syngene International Ltd.
Syngene International Ltd. operates in the biotechnology sector, providing integrated research, development, and manufacturing services. The company focuses on delivering scientific solutions to the pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors.
YTD Price Performance: -14.61%
Average Trading Volume: 44,654
Current Market Cap: 296B INR
For an in-depth examination of SYNGENE stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money